Pharmacologic adjunctive to insulin therapies in type 1 diabetes: The journey has just begun

Treatment of type 1 diabetes (T1D) is currently based exclusively on insulin replacement therapy. However, there is a need for better glycemic control, lower hypoglycemia rates, more effective weight management, and further reduction of cardiovascular risk in people with T1D. In this context, agents...

Descripción completa

Detalles Bibliográficos
Autores principales: Karras, Spyridon N, Koufakis, Theocharis, Zebekakis, Pantelis, Kotsa, Kalliopi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475707/
https://www.ncbi.nlm.nih.gov/pubmed/31040899
http://dx.doi.org/10.4239/wjd.v10.i4.234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475707/
https://www.ncbi.nlm.nih.gov/pubmed/31040899
http://dx.doi.org/10.4239/wjd.v10.i4.234

Ejemplares similares